XML 48 R7.htm IDEA: XBRL DOCUMENT v3.20.1
Basis of Presentation and Significant Accounting Policies
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Basis of Presentation and Significant Accounting Policies
Note 1
-
 Basis of Presentation and Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements of iCAD, Inc. and subsidiaries (“iCAD” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of management, these unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position of the Company at March 31, 2020, the results of operations of the Company for the three- month period ended March 31, 2020 and 2019, and cash flows of the Company for the three-month period ended March 31, 2020 and 2019.
Although the Company believes that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (“SEC”). The accompanying financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form
10-K
for the fiscal year ended December 31, 2019 filed with the SEC on March 11, 2020. The results for the three-month period ended March 31, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2020, or any future period.
Segments
The Company reports the results of two segments: Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of advanced image analysis and workflow products. The Therapy segment consists of radiation therapy (“Axxent”) products.
Risk and Uncertainty
On March 12, 2020, the World Health Organization declared
COVID-19
to be a pandemic. In an effort to contain and mitigate the spread of
COVID-19,
many countries, including the United States, Canada and China, have imposed unprecedented restrictions on travel, and there have been business closures and a substantial reduction in economic activity in countries that have had significant outbreaks of
COVID-19.
As a provider of devices and services to the health care industry, our operations have been materially affected. Significant uncertainty remains as to the potential impact of the
COVID-19
pandemic on our continuing operations and on the global economy as a whole. It is currently not possible to predict how long the pandemic will last or the time that it will take for economic activity to return to prior levels. The
COVID-19
pandemic has resulted in significant financial market volatility and uncertainty. A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital, on our business, results of operations and financial condition, and on the market price of our common stock. Accessing capital may be impacted by the fact that there is a minimum revenue covenant contained in the Company’s Loan and Security Agreement with Western Alliance Bank (see note 4 (b) for details) that could be impacted by the COVID 19 pandemic. If at any point the Company is not in compliance with such covenant and is unable to obtain an amendment or waiver, such noncompliance may result in an event of default under the Loan and Security Agreement, which could result in acceleration of the outstanding indebtedness and require the Company to repay such indebtedness before the scheduled due date.
The Company believes even if that event of default were to occur, the Company’s current liquidity and capital resources are sufficient to sustain operations through at least the next 12 months, primarily due to cash on hand, which now includes an additional estimated $12.2 million the Company received following the sale of 1,562,500 shares of the Company’s common stock at $8.00 per share, pursuant to a registered direct offering which closed on April 27, 2020.
Our results for the quarter ending March 31, 2020 reflect a negative impact from, among other things, the 
COVID-19
 pandemic as shipping, logistics, acceptance and installation and training have been delayed and ordering patterns disrupted. Although we do not provide guidance to investors relating to our future results of operations, we expect that our results for the quarter ending June 30, 2020, and possibly future quarters, will reflect a negative impact from the 
COVID-19
 pandemic for similar reasons. Depending upon the duration and severity of the pandemic, the continuing effect on our results over the long term is uncertain.
The Company’s exposure to trade accounts receivable losses may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current
COVID-19
pandemic, or other customer-specific factors. Although the Company has historically not experienced significant trade account receivable losses, it is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade account receivables as hospitals’ cash flows are impacted by their response to the
COVID-19
pandemic.
Recently Adopted Accounting Pronouncements
There are
 no
 significant recently adopted accounting pronouncements. For a full list of the Company’s response to all recent accounting pronouncements please refer to Note 13 below.
Revenue Recognition
Revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration which the Company expects to be entitled to receive in exchange for these goods or services and excludes any sales incentives or taxes collected from customer
s
which are subsequently remitted to government authorities.
 
Disaggregation of Revenue
The following tables presents our revenues disaggregated by major good or service line, timing of revenue recognition, and sales channel, reconciled to our reportable segments (in thousands).
 
   
Three months ended March 31, 2020
 
   
Reportable Segments
     
   
Detection
   
Therapy
   
Total
 
Major Goods/Service Lines
      
Products
  $3,100   $1,346   $4,446 
Service contracts
   1,347    347    1,694 
Supply and source usage agreements
   —      371    371 
Professional services
   —      11    11 
Other
   29    —      29 
  
 
 
   
 
 
   
 
 
 
  $4,476   $2,075   $6,551 
  
 
 
   
 
 
   
 
 
 
Timing of Revenue Recognition
      
Goods transferred at a point in time
  $3,129   $1,383   $4,512 
Services transferred over time
   1,347    692    2,039 
  
 
 
   
 
 
   
 
 
 
  $4,476   $2,075   $6,551 
  
 
 
   
 
 
   
 
 
 
Sales Channels
      
Direct sales force
  $2,172   $1,469   $3,641 
OEM partners
   2,304    —      2,304 
Channel partners
   —      606    606 
  
 
 
   
 
 
   
 
 
 
  $4,476   $2,075   $6,551 
  
 
 
   
 
 
   
 
 
 
 
   
Three months ended March 31, 2019
 
   
Reportable Segments
     
   
Detection
   
Therapy
   
Total
 
Major Goods/Service Lines
      
Products
  $2,790   $1,519   $4,309 
Service contracts
   1,322    516    1,838 
Supply and source usage agreements
   —      537    537 
Professional services
   —      33    33 
Other
   56    —      56 
  
 
 
   
 
 
   
 
 
 
  $4,168   $2,605   $6,773 
  
 
 
   
 
 
   
 
 
 
Timing of Revenue Recognition
      
Goods transferred at a point in time
  $2,790   $1,632   $4,422 
Services transferred over time
   1,378    973    2,351 
  
 
 
   
 
 
   
 
 
 
  $4,168   $2,605   $6,773 
  
 
 
   
 
 
   
 
 
 
Sales Channels
      
Direct sales force
  $2,057   $1,812   $3,869 
OEM partners
   2,111    —      2,111 
Channel partners
   —      793    793 
  
 
 
   
 
 
   
 
 
 
  $4,168   $2,605   $6,773 
  
 
 
   
 
 
   
 
 
 
Products.
Product revenue consists of sales of cancer detection products, cancer therapy systems, cancer therapy applicators (including disposable applicators) and other accessories that are typically shipped with a cancer therapy system. The Company transfers control and recognizes a sale when the product is shipped from the manufacturing or warehousing facility to the customer.
Service Contracts.
The Company sells service contracts in which it provides professional services including product installations, maintenance, training, and service repairs, and in certain cases leases equipment, to hospitals, imaging centers, radiology practices, radiation oncologists and treatment centers. These represent separate performance obligations to the Company. The Company allocates revenue to each performance obligation based on the Standalone Selling Price (“SSP”). Upon the Company’s adoption of ASC 842 effective January 1, 2019, the lease components of the Company’s service contracts are no longer being separately accounted for under the lease guidance. As the lease component is not considered the predominant component of these service contracts, the Company is accounting for the whole contract under ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). Prior to the adoption of ASC 842, the Company accounted for the lease components of these arrangements in accordance with ASC 840 and the remaining consideration was allocated to the other performance obligations identified in accordance with ASC 606. The consideration allocated to the lease component was recognized as lease revenue on a straight-line basis over the specified term of the agreement, as this is consistent with how the service is consumed. Revenue for the
non-lease
components, or the entire arrangement when accounted for under ASC 606, is recognized on a straight-line basis over the term of the agreement. The service contracts range from 12 months to 48 months. The Company typically receives payment at the inception of the contract and recognizes revenue on a straight-line basis over the term of the agreement.
Supply and Source Usage Agreements.
Revenue from supply and source usage agreements is recognized on a straight-line basis over the term of the supply or source usage agreement. These agreements represent a separate performance obligation to the Company. The Company allocates revenue to each performance obligation based on the SSP.
Professional Services.
Revenue from fixed fee service contracts is recognized on a straight-line basis over the term of the agreement. Revenue from professional service contracts entered into with customers on a time and materials basis is recognized over the term of the agreement in proportion to the costs incurred in satisfying the obligations under the contract.
Other.
Other revenue consists primarily of miscellaneous products and services. The Company transfers control and recognizes a sale when the installation services are performed or when the product is shipped from the manufacturing or warehousing facility to the customer.
Contract Balances
Contract liabilities are a component of deferred revenue, and contract assets are a component of prepaid and other current assets. The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (in thousands).
Contract balances
 
   
Balance at
March 31, 2020
 
Receivables, which are included in ‘Trade accounts receivable’
  $7,090 
Contract assets, which are included in “Prepaid and other current assets”
   14 
Contract liabilities, which are included in “Deferred revenue”
   5,491 
Timing of revenue recognition may differ from timing of invoicing to customers. The Company records a receivable when revenue is recognized prior to receipt of cash payment and the Company has the unconditional right to such consideration, or unearned revenue when cash payments are received or due in advance of performance. For multi-year agreements, the Company generally invoices customers annually at the beginning of each annual service period.
 
The Company’s accounts receivable from contracts with customers, net of allowance for doubtful accounts, was $7.1 million and $9.8 million as of March 31, 2020 and December 31, 2019, respectively.
The Company will record a contract asset for unbilled revenue when the Company’s performance is in excess of amounts billed or billable. The Company has classified the contract asset balance as a component of prepaid expenses and other current assets as of March 31, 2020 and December 31, 2019. The contract asset balance was $14,000 as of March 31, 2020 and December 31, 2019.
Deferred revenue from contracts with customers is primarily composed of fees related to long-term service arrangements, which are generally billed in advance. Deferred revenue also includes payments for installation and training that has not yet been completed and other offerings for which we have been paid in advance and earn the revenue when we transfer control of the product or service. Deferred revenue from contracts with customers is included in deferred revenue in the consolidated balance sheets.
The balance of deferred revenue at March 31, 2020 and December 31, 2019 is as follows (in thousands):
Contract liabilities
 
 
  
March 31, 2020
 
  
December 31, 2019
 
Short term
  
$
5,259
 
  
$
5,248
 
Long term
  
 
232
 
  
 
356
 
 
  
 
 
 
  
 
 
 
Total
  
$
5,491
 
  
$
5,604
 
 
  
 
 
 
  
 
 
 
Changes in deferred revenue from contracts with customers were as follows (in thousands):
 
   
Three Months Ended

March 31, 2020
 
Balance at beginning of period
  $5,604 
Deferral of revenue
   2,226 
Recognition of deferred revenue
   (2,339
  
 
 
 
Balance at end of period
  $5,491 
  
 
 
 
We expect to recognize approximately $4.8 million of the deferred amount in 2020, $0.5 million in 2021, and $0.2 million thereafter.